MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Artelo Biosciences Operating Income 2011-2026 | ARTL
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Artelo Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -11.4 M | -10.1 M | -9.93 M | -10.3 M | -4.04 M | -4.69 M | -3.21 M | -2.34 M | -233 K | -29.7 K | -15.2 K | -15.3 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -15.2 K | -11.4 M | -4.69 M |
Quarterly Operating Income Artelo Biosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.09 M | -3.15 M | -2.38 M | - | -1.2 M | -2.51 M | -2.59 M | - | -2.61 M | -1.78 M | -2.29 M | - | -2.39 M | -2.47 M | -1.95 M | -2.55 M | -2.24 M | -2.25 M | -1.7 M | -1.44 M | -3.66 M | -951 K | -1.44 M | -1.34 M | -2.26 M | -941 K | -1.34 M | -557 K | -1.65 M | -578 K | -557 K | -277 K | -117 K | -95.7 K | -277 K | -9.52 K | - | -5.05 K | -9.52 K | -15.2 K | -10.6 K | -2.5 K | -15.2 K | -2 K | -14.7 K | -8.15 K | -6.6 K | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -2 K | -3.66 M | -1.27 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
231 M | $ 22.56 | 2.13 % | $ 3.74 B | USA |
 |
AlloVir
ALVR
|
-46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |
 |
Applied Therapeutics
APLT
|
-64.5 M | - | - | $ 8.42 M | USA |
 |
Akebia Therapeutics
AKBA
|
23.5 M | $ 1.43 | 3.62 % | $ 368 M | USA |
 |
argenx SE
ARGX
|
-349 M | $ 785.07 | 2.57 % | $ 25 B |  Niderland |
 |
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B |  France |
 |
Alnylam Pharmaceuticals
ALNY
|
502 M | $ 327.25 | 2.42 % | $ 42.9 B | USA |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | France |
 |
Aytu BioScience
AYTU
|
-7.83 M | $ 2.66 | 3.5 % | $ 16.7 M | USA |
 |
AVROBIO
AVRO
|
10.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
1.06 B | - | - | $ 96.9 B |  Britain |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | Britain |
 |
BeiGene, Ltd.
BGNE
|
447 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
CymaBay Therapeutics
CBAY
|
-102 M | - | - | $ 3.45 B | USA |
 |
Advaxis
ADXS
|
-36.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
140 M | $ 20.4 | -0.87 % | $ 954 M | USA |
 |
Aquestive Therapeutics
AQST
|
-71.1 M | $ 4.18 | 1.21 % | $ 447 M | USA |
 |
Avid Bioservices
CDMO
|
-18.7 M | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
-176 M | - | - | $ 1.41 B | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-12.2 M | $ 24.61 | 5.76 % | $ 3.13 B | USA |
 |
Cabaletta Bio
CABA
|
-172 M | $ 3.09 | 0.65 % | $ 310 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
-56.2 M | - | - | $ 169 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M |  Canada |
 |
Checkmate Pharmaceuticals
CMPI
|
-61.5 M | - | - | $ 231 M | USA |
 |
AgeX Therapeutics
AGE
|
-24 M | - | -10.17 % | $ 12.2 K | USA |
 |
Concert Pharmaceuticals
CNCE
|
-77.5 M | - | - | $ 401 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-271 M | $ 1.49 | 9.56 % | $ 397 M | Britain |
 |
CTI BioPharma Corp.
CTIC
|
-79.8 M | - | - | $ 1.2 B | USA |
 |
AIkido Pharma
AIKI
|
-55.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-8.43 M | - | -4.36 % | $ 27 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-211 M | - | - | $ 2.18 B | USA |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
-4.12 M | - | - | $ 2.02 B | USA |
|
Forte Biosciences
FBRX
|
-70.7 M | $ 26.27 | 0.38 % | $ 340 M | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Akari Therapeutics, Plc
AKTX
|
-17.3 M | $ 3.88 | 2.11 % | $ 261 B | Britain |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |